TCGA-B6-A0RP-01A-21R-A084-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 104
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- TGF_BETA_SIGNALING+0.340
- UV_RESPONSE_DN+0.320
- TNFA_SIGNALING_VIA_NFKB+0.270
- ANGIOGENESIS+0.250
- NOTCH_SIGNALING+0.230
- WNT_BETA_CATENIN_SIGNALING+0.210
- PROTEIN_SECRETION+0.140
- APOPTOSIS+0.120
- APICAL_SURFACE+0.110
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.570
- MYC_TARGETS_V1-0.530
- MYC_TARGETS_V2-0.520
- MTORC1_SIGNALING-0.410
- OXIDATIVE_PHOSPHORYLATION-0.330
- SPERMATOGENESIS-0.290
- DNA_REPAIR-0.240
- MITOTIC_SPINDLE-0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.890 |
| 2 | b483502d-4e7f-46ff-b0f2-e35c51047efb | — | — | 0.852 |
| 3 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.849 |
| 4 | 20020074.LumA | — | A | 0.847 |
| 5 | TCGA-69-7763-01A-11R-2170-07 | — | cohortA2 | 0.845 |
| 6 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.845 |
| 7 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.843 |
| 8 | SRR5088925 | — | — | 0.840 |
| 9 | TCGA-05-4405-01A-21R-1858-07 | — | cohortA1 | 0.829 |
| 10 | SRR2932823 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |